| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 248.84% | Needham | → $6 | Reiterates | Buy → Buy |
| 05/05/2023 | 248.84% | Needham | → $6 | Reiterates | → Buy |
| 03/03/2023 | 248.84% | Needham | → $6 | Reiterates | → Buy |
| 11/04/2022 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 11/04/2022 | 248.84% | Needham | $12 → $6 | Maintains | Buy |
| 11/04/2022 | 248.84% | Piper Sandler | $13 → $6 | Maintains | Overweight |
| 08/23/2022 | 772.09% | Truist Securities | $19 → $15 | Maintains | Buy |
| 05/23/2022 | 655.81% | Piper Sandler | $21 → $13 | Maintains | Overweight |
| 03/01/2022 | 830.23% | Ladenburg Thalmann | → $16 | Initiates Coverage On | → Buy |
| 11/05/2021 | 713.95% | Needham | $30 → $14 | Maintains | Buy |
| 03/05/2021 | 1004.65% | Truist Securities | $13 → $19 | Upgrades | Hold → Buy |
| 01/15/2021 | 481.4% | B of A Securities | $13 → $10 | Downgrades | Neutral → Underperform |
| 07/16/2020 | 888.37% | Benchmark | → $17 | Upgrades | Hold → Buy |
| 07/14/2020 | 1469.77% | BTIG | $61 → $27 | Maintains | Buy |
| 07/13/2020 | 655.81% | SunTrust Robinson Humphrey | $78 → $13 | Downgrades | Buy → Hold |
| 06/01/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/08/2020 | 3039.53% | Morgan Stanley | $58 → $54 | Maintains | Overweight |
| 04/15/2020 | 3272.09% | Morgan Stanley | $55 → $58 | Maintains | Overweight |
| 03/02/2020 | 4551.16% | Roth Capital | → $80 | Initiates Coverage On | → Buy |
| 01/13/2020 | 4434.88% | SunTrust Robinson Humphrey | → $78 | Initiates Coverage On | → Buy |
| 12/17/2019 | 3097.67% | Morgan Stanley | $52 → $55 | Maintains | Overweight |
| 11/26/2019 | 3446.51% | BTIG | → $61 | Initiates Coverage On | → Buy |
| 11/13/2019 | 2923.26% | Morgan Stanley | $33 → $52 | Maintains | Overweight |
| 11/12/2019 | 5074.42% | B of A Securities | $92 → $89 | Reiterates | → Buy |
| 09/09/2019 | 2458.14% | B of A Securities | $27 → $44 | Reiterates | → Buy |
| 09/05/2019 | 3039.53% | Piper Sandler | $26 → $54 | Maintains | Overweight |
| 08/13/2019 | 1818.6% | Morgan Stanley | $25 → $33 | Maintains | Overweight |
| 07/09/2019 | — | B of A Securities | Initiates Coverage On | → Buy | |
| 06/03/2019 | 1353.49% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 1411.63% | Piper Sandler | → $26 | Initiates Coverage On | → Overweight |
What is the target price for NextCure (NXTC)?
The latest price target for NextCure (NASDAQ: NXTC) was reported by Needham on August 4, 2023. The analyst firm set a price target for $6.00 expecting NXTC to rise to within 12 months (a possible 248.84% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NextCure (NXTC)?
The latest analyst rating for NextCure (NASDAQ: NXTC) was provided by Needham, and NextCure reiterated their buy rating.
When is the next analyst rating going to be posted or updated for NextCure (NXTC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
Is the Analyst Rating NextCure (NXTC) correct?
While ratings are subjective and will change, the latest NextCure (NXTC) rating was a reiterated with a price target of $0.00 to $6.00. The current price NextCure (NXTC) is trading at is $1.72, which is within the analyst's predicted range.